Canaccord Genuity Reiterates a Buy on Biogen (BIIB)

Group 1 - Biogen Inc. is considered one of the best drug stocks to buy currently, with a Buy rating and a price target of $220.00 set by Canaccord Genuity [1] - In fiscal Q2 2025, Biogen reported total revenue of $2.6 billion, reflecting a 7% year-over-year increase [2] - The GAAP diluted EPS for the quarter was $4.33, up 8% year-over-year, while the non-GAAP diluted EPS rose 4% year-over-year to $5.47 [2] Group 2 - Biogen's medicine portfolio includes treatments for multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS) [3]